Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up As of the clinical cutoff ...
Asianet Newsable on MSN
NeOnc Technologies receives UAE IND approval for NEO100, expanding global development ahead of anticipated phase 2 data milestone
Authorization covers all three NEO100 programs across adult Phase 1 through Phase 2, plus pediatric studies< Extends NeOnc’s ...
Continuous process improvement can benefit all aspects of life — from personal New Year’s resolutions to complex drug development. In a world where two-thirds of planned improvement initiatives fail, ...
This Brush Up is sponsored by MilliporeSigma. Learn more about therapeutic synthesis pathways. Drug development is a process that spans many years, from the initial phase of identifying potential drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results